Arguments against routine administration of probiotics for NEC prevention

Current Opinion in Pediatrics

Volumn 31, Issue 2, 2019, Pages 195-201

  Pell, Lisa G ^a   Loutet, Miranda G ^a   Roth, Daniel E ^a   Sherman, Philip M ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

Intestine; Necrotizing enterocolitis; Prematurity; Probiotics

Indexed keywords

PROBIOTIC AGENT;

DRUG FORMULATION; DRUG QUALITY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; HUMAN; NECROTIZING ENTEROCOLITIS; PREMATURITY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; NEONATAL INTENSIVE CARE UNIT; NEWBORN; NEWBORN DISEASE;

ENTEROCOLITIS, NECROTIZING; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFANT, PREMATURE; INTENSIVE CARE UNITS, NEONATAL; PROBIOTICS;

EID: 85062616730     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000730     Document Type: Review

References (76)

1. Isani MA, Delaplain PT, Grishin A, Ford HR. Evolving understanding of && neonatal necrotizing enterocolitis. Curr Opin Pediatr 2018; 30:417-423. Recent overview of the multifactorial pathogenesis of NEC and brief summary of the most promising preventive measures.
2. Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015; 314:1039-1051.
3. Younge N, Goldstein RF, Bann CM, et al. Survival and && neurodevelopmental outcomes among periviable infants. N Engl J Med 2017; 376:617-628. Large study reporting a recent and accurate estimate of the incidence of NEC among extremely preterm and very low birth weight infants.
4. Patel RM, Kandefer S, Walsh MC, et al. Causes and timing of death in extremely premature infants from 2000 through 2011. N Engl J Med 2015; 372:331-340.
5. Elfvin A, Dinsdale E, Wales PW, Moore AM. Low birthweight, gestational age, need for surgical intervention and gram-negative bacteraemia predict intestinal failure following necrotising enterocolitis. Acta Paediatr 2015; 104:771-776.
6. Gaudin A, Farnoux C, Bonnard A, et al. Necrotizing enterocolitis (NEC) and the risk of intestinal stricture: the value of C-reactive protein. PLoS One 2013; 8:e76858.
7. Synnes A, Luu TM, Moddemann D, et al. Determinants of developmental outcomes in a very preterm Canadian cohort. Arch Dis Child Fetal Neonatal Ed 2017; 102:F235-F234.
8. Heida FH, Stolwijk L, Loos M-LHJ, et al. Increased incidence of necrotizing enterocolitis in the Netherlands after implementation of the new Dutch guideline for active treatment in extremely preterm infants: results from three academic referral centers. J Pediatr Surg 2017; 52:273-276.
9. Berrington JE, Hearn RI, Bythell M, et al. Deaths in preterm infants: changing pathology over 2 decades. J Pediatr 2012; 160:49-53.
10. Ahle M, Drott P, Andersson RE. Epidemiology and trends of necrotizing enterocolitis in Sweden: 1987-2009. Pediatrics 2013; 132:e443-e451.
11. Lenfestey MW, de la Cruz D, Neu J. Food protein-induced enterocolitis instead of necrotizing enterocolitis? A neonatal intensive care unit case series. J Pediatr 2018; 200:270-273.
12. Nino DF, Sodhi CP, Hackam DJ. Necrotizing enterocolitis: new insights into pathogenesis and mechanisms. Nature reviews. Gastroenterol Hepatol 2016; 13:590-600.
13. Pammi M, Cope J, Tarr PI, et al. Intestinal dysbiosis in preterm infants && preceding necrotizing enterocolitis: a systematic review and meta-analysis. Microbiome 2017; 5:31. Systematic review and meta-analysis of recent evidence demonstrating that specific changes in the infant microbiome precede the onset on NEC.
14. Warner BB, Deych E, Zhou Y, et al. Gut bacteria dysbiosis and necrotising enterocolitis in very low birthweight infants: a prospective case-control study. Lancet 2016; 387:1928-1936.
15. Hill C, Guarner F, Reid G, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11:506-514.
16. Ishizeki S, Sugita M, Takata M, Yaeshima T. Effect of administration of bifidobacteria on intestinal microbiota in low-birth-weight infants and transition of administered bifidobacteria: a comparison between one-species and three-species administration. Anaerobe 2013; 23:38-44.
17. Wu RY, Pasyk M, Wang B, et al. Spatiotemporal maps reveal regional differences in the effects on gut motility for Lactobacillus reuteri and rhamnosus strains. Neurogastroenterol Motil 2013; 25: e205 - e214.
18. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121:580-591.
19. Mangell P, Nejdfors P, Wang M, et al. Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability. Diges Dis Sci 2002; 47:511-516.
20. Underwood MA. Probiotics and innate and adaptive immune responses in & premature infants. Forum on immunopathological diseases and therapeutics 2016; 7:1-15. This review provides a detailed overview of how the most commonly used probiotic strain impact innate and adaptive immune responses by summarizing in vitro and animal model studies and clinical trials of preterm infants.
21. van den Akker CHP, van Goudoever JB, Szajewska H, et al. Probiotics for && Preterm Infants: a strain specific systematic review and network meta-analysis. J Pediatr Gastroenterol Nutr 2018; 67:. Recent systematic review and meta-analysis of randomized control trials using probiotics and the effect on NEC, sepsis, and death among preterm infants. The present review is unique in applying network meta-analytical techniques to combine results from RCTs that use different probiotic strains.
22. Thomas JP, Raine T, Reddy S, Belteki G. Probiotics for the prevention of & necrotising enterocolitis in very-low-birthweight infants: a meta-analysis of randomised controlled trials. Gut 2017; 66:A113. Meta-analysis demonstrating the importance of conducting probiotic clinical trials among extremely low birth weight infants who are at highest risk of NEC.
23. Deshpande G, Jape G, Rao S, Patole S. Benefits of probiotics in preterm & neonates in low-income and medium-income countries: a systematic review of randomised controlled trials. BMJ open 2017; 7:e017638. Systematic review and meta-analysis demonstrating that probiotics represent a promising preventive intervention in low-income and medium-income countries.
24. Sawh SC, Deshpande S, Jansen S, et al. Prevention of necrotizing enter- & ocolitis with probiotics: a systematic review and meta-analysis. Peer J 2016; 2016(10). Recent systematic review and meta-analysis of the efficacy of probiotics among preterm and low birth weight infants. The meta-analysis pooled all randomized control trials that reported on NEC as an outcome, regardless of probiotic strain used.
25. Aceti A, Gori D, Barone G, et al. Probiotics for prevention of necrotizing enterocolitis in preterm infants: systematic review and meta-analysis. Italian J Pediatr 2015; 41:89.
26. Al Faleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Evidence-Based Child Health 2014; 9:584-671.
27. Yang Y, Guo Y, Kan Q, et al. A meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Braz J Med Biol Res 2014; 47:804-810.
28. Underwood MA. Probiotics and the prevention of necrotizing enterocolitis. J & Pediatr Surg 2018. [Epub ahead of print] This recent review summarizes evidence for the use of probiotics among preterm infants in the NICU, but urges that probiotics should only be administered if produced under high standards with strict quality control.
29. Patole S. Probiotics for preterm infants - the story searching for an end. Indian Pediatr 2017; 54:361-362.
30. Deshpande G, Rao S, Patole S. Probiotics in neonatal intensive care - back to the future. Aust N Z J Obstet Gynaecol 2015; 55:210-217.
31. Ofek Shlomai N, Deshpande G, Rao S, Patole S. Probiotics for preterm neonates: what will it take to change clinical practice? Neonatology 2014; 105:64-70.
32. Viswanathan S, Lau C, Akbari H, et al. Survey and evidence based review of probiotics used in very low birth weight preterm infants within the United States. J Perinatol 2016; 36:1106-1111.
33. McFarland LV, Evans CT, Goldstein EJC. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med (Lausanne) 2018; 5:124.
34. Costeloe K, Hardy P, Juszczak E, et al. Bifidobacterium breve BBG-001 in & very preterm infants: a randomised controlled phase 3 trial. Lancet 2016; 387:649-660. Large randomized control trial of probiotics in preterm infants. The PiPs trial did not find a significant reduction in NEC. The authors highlighted the importance of sampling to identify cross-colonization of the placebo group.
35. Jacobs SE, Tobin JM, Opie GF, et al. Probiotic effects on late-onset sepsis in very preterm infants: a randomized controlled trial. Pediatrics 2013; 132:1055-1062.
36. Kane AF, Bhatia AD, Denning PW, et al. Routine supplementation of Lactobacillus rhamnosus GG and risk of necrotizing enterocolitis in very low birth weight infants. J Pediatr 2018; 195:73.
37. Mihatsch WA, Braegger CP, Decsi T, et al. Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. Clin Nutr 2012; 31:6-15.
38. Embleton ND, Zalewski S, Berrington JE. Probiotics for prevention of necrotizing enterocolitis and sepsis in preterm infants. Curr Opin Infect Dis 2016; 29:256-261.
39. Miller J, Tonkin E, Damarell R, et al. A systematic review and meta-analysis of human milk feeding and morbidity in very low birth weight infants. Nutrients 2018; 10:707.
40. Sharpe J, Way M, Koorts PJ, Davies MW. The availability of probiotics and donor human milk is associated with improved survival in very preterm infants. World J Pediatr 2018; 14:492-497.
41. Xu W, Judge MP, Maas K, et al. Systematic review of the effect of enteral feeding on gut microbiota in preterm infants. J Obstet Gynecol Neonatal Nurs 2018; 47:451-463.
42. Underwood MA, Sohn K. The microbiota of the extremely preterm infant. Clin Perinatol 2017; 44:407-427.
43. Al-Hosni M, Duenas M, Hawk M et al. Probiotics-supplemented feeding in extremely low-birth-weight infants. J Perinatol 2012;32:253.
44. Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics 2008; 122:693-700.
45. Oncel MY, Sari FN, Arayici S, et al. Lactobacillus Reuteri for the prevention of necrotising enterocolitis in very low birthweight infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2014; 99:F110-F115.
46. Bernstein IM, Horbar JD, Badger GJ, et al. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. Am J Obstet Gynecol 2000; 182:198-206.
47. Patole S. Probiotic supplementation for preterm neonates-what lies ahead? Nestle Nutr Inst Workshop Ser 2015; 81:153-162.
48. Patole SK, Rao SC, Keil AD, et al. Benefits of Bifidobacterium breve M-16V supplementation in preterm neonates-a retrospective cohort study. PLoS One 2016; 11:e0150775.
49. Sharma R, Hudak ML. A clinical perspective of necrotizing enterocolitis: past, present, and future. Clin Perinatol 2013; 40:27-51.
50. Dilli D, Aydin B, Zenciroglu A, et al. Treatment outcomes of infants with cyanotic congenital heart disease treated with symbiotic. Pediatrics 2013; 132:e932-e938.
51. El-Sawaf M, Siddiqui S, Mahmoud M, et al. Probiotic prophylaxis after pull through for Hirschsprung disease to reduce incidence of enterocolitis: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. J Pediatr Surg 2013; 48:111-117.
52. Tuomola E, Crittenden R, Playne M, et al. Quality assurance criteria for probiotic bacteria-. Am J Clin Nutr 2001; 73:393s-398s.
53. Grzeskowiak Ł, Isolauri E, Salminen S, Gueimonde M. Manufacturing process influences properties of probiotic bacteria. Br J Nutr 2011; 105:887-894.
54. Elo S, Saxelin M, Salminen S. Attachment of Lactobacillus casei strain GG to human colon carcinoma cell line Caco-2: comparison with other dairy strains. Lett Appl Microbiol 1991; 13:154-156.
55. Deepika G, Green RJ, Frazier RA, Charalampopoulos D. Effect of growth time on the surface and adhesion properties of Lactobacillus rhamnosus GG. J Appl Microbiol 2009; 107:1230-1240.
56. FAO/WHO. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria 2001.
57. Food and Agriculture Organization WHO. Probiotics in Food: Health and && nutritional properties and guidelines for evaluation. In: Report of a Joint FAO/ WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. 2006. Current global recommendations on the information that should be included on probiotic product labels for the purpose of quality control and standardization, including the identity of bacterial species and number of viable cells for each organism.
58. Kolacek S, Hojsak I, Berni Canani R, et al. Commercial probiotic products: a call && for improved quality control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr 2017; 65:117-124. Systematic review of studies demonstrating the quality control errors that exist in the labeling and composition (species and number of cells) of commercially available probiotic products.
59. Drago L, Rodighiero V, Celeste T, et al. Microbiological evaluation of commercial probioticproductsavailableintheUSAin2009.JChemother2010;22:373-377.
60. Lewis ZT, Shani G, Masarweh CF, et al. Validating bifidobacterial species and subspecies identity in commercial probiotic products. Pediatr Res 2016; 79:445-452.
61. Tarnow-Mordi W, Soll RF. Probiotic supplementation in preterm infants: it is time to change practice. J Pediatr 2014; 164:959-960.
62. Taylor RS. Probiotics to prevent necrotizing enterocolitis: too cheap and easy? Paediatr Child Health (Canada) 2014; 19:351-352.
63. Robinson J. Cochrane in context: probiotics for prevention of necrotizing enterocolitis in preterm infants. Evid Based Child Health 2014; 9:672-674.
64. Mattia A, Merker R. Regulation of probiotic substances as ingredients in foods: premarket approval or 'generally recognized as safe' notification. Clin Infect Dis 2008; 46:S115-S118.
65. Abrahamsson TR, Rautava S, Moore AM, et al. The time for a confirmative necrotizing enterocolitis probiotics prevention trial in the extremely low birth weight infant in North America is now! J Pediatr 2014; 165:389-394.
66. Hickey L, Garland SM, Jacobs SE, et al. Cross-colonization of infants with probiotic organisms in a neonatal unit. J Hosp Infect 2014; 88:226-229.
67. Zbinden A, Zbinden R, Berger C, Arlettaz R. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 2015; 107:56-59.
68. Bertelli C, Pillonel T, Torregrossa A, et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 2015; 60:924-927.
69. Sadowska-Krawczenko I, Korbal P, Polak A, et al. Lactobacilllus rhamnosus ATC A07FA for preventing necrotizing enterocolitis in very-low-birth-weight preterm infants: a randomized controlled trial (preliminary results). Pediatria Polska 2012; 87:139-145.
70. Borriello SP, Hammes WP, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003; 36:775-780.
71. Marteau P. Safety aspects of probiotic products. Näringsforskning 2001; 45:22-24.
72. Esaiassen E, Cavanagh P, Hjerde E, et al. Bifidobacterium longum subspecies & infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis 2016; 22:1664-1666. Recent evidence of probiotic bacteremia using a commonly used commercial probiotic product among preterm infants in Norway.
73. Avcin SL, Pokorn M, Kitanovski L, et al. Bifidobacterium breve sepsis in child with high-risk acute lymphoblastic leukemia. Emerg Infect Dis 2015; 21:1674-1675.
74. Bafeta A, Koh M, Riveros C, Ravaud P. Harms reporting in randomized && controlled trials of interventions aimed at modifying microbiota: a systematic review. Ann Intern Med 2018; 169:240-247. Systematic review that assesses the level of safety reported by randomized control trials using probiotics in preterm infants.
75. Davis C. Enumeration of probiotic strains: review of culture-dependent and alternative techniques to quantify viable bacteria. J Microbiol Methods 2014; 103:9-17.
76. Fasano A. Gut microbiome and necrotising enterocolitis: time for interven- & tion? Lancet 2016; 387:1884-1885. This commentary provides insightful and innovative suggestions to use probiotics as a form of personalized medicine, taking into consideration infants with the highest risk of NEC.